DFCM
ABCL icon

Dark Forest Capital Management’s AbCellera Biologics ABCL Stock Holding History

Dark Forest Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-146,001
Closed -$432K – 938
2024
Q2 		$432K Buy
146,001
+45,721
+46% +$173K 0.08% 306
2024
Q1 		$454K Buy
100,280
+89,790
+856% +$458K 0.08% 313
2023
Q4 		$59.9K Sell
10,490
-268,128
-96% -$1.24M 0.01% 419
2023
Q3 		$1.28M Buy
278,618
+185,606
+200% +$1.13M 0.1% 312
2023
Q2 		$601K Buy
93,012
+77,822
+512% +$531K 0.06% 559
2023
Q1 		$115K Buy
15,190
+13,677
+904% +$124K 0.03% 612
2022
Q4 		$15.3K Buy
1,513
+1,229
+433% +$14.2K ﹤0.01% 638
2022
Q3 		$3K Sell
284
-1,985
-87% -$21.8K ﹤0.01% 959
2022
Q2 		$24K Sell
2,269
-8,809
-80% -$74.6K 0.01% 461
2022
Q1 		$108K Buy
11,078
+7,894
+248% +$74.7K 0.03% 482
2021
Q4 		$46K Buy
+3,184
New +$48.3K 0.02% 467
2021
Q3 		– Sell
-157
Closed -$3K – 1222
2021
Q2 		$3K Buy
+157
New +$4.33K ﹤0.01% 729

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dark Forest Capital Management's ABCL Position: Q3 2024 in Review

Dark Forest Capital Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 146,001 shares — an estimated $432K sold.

Dark Forest Capital Management first reported a position in ABCL in Q2 2021 and held it in 12 quarters. The position peaked at $1.28M in Q3 2023. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Dark Forest Capital Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Dark Forest Capital Management sold 146,001 AbCellera Biologics shares in Q3 2024, an estimated $432K.
  • Dark Forest Capital Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 12 quarters.
  • Dark Forest Capital Management's AbCellera Biologics position peaked at $1.28M in Q3 2023.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Dark Forest Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.